Cosmetic Surgery Sees Surge in Demand as Weight-Loss Drugs Lead to 'Ozempic Body'

The widespread adoption of weight-loss medications like Ozempic, Wegovy, and Mounjaro has ushered in a new wave of demand for cosmetic surgery, with many patients seeking to address the physical consequences of rapid weight loss, often referred to as the 'Ozempic body.' Breast augmentation and lifts are among the most sought-after procedures, as the loss of fat can leave breasts deflated and skin loose.

Consultant plastic surgeon Adrian Richards noted that breast surgery is the number one request he receives, followed by procedures for the abdomen, face, arms, and thighs. He described the current situation as the 'second wave of the GLP-1 revolution,' where the initial focus on weight loss is shifting to managing the resulting body changes.

Nora Nugent, a cosmetic plastic surgeon and president of the British Association of Aesthetic Plastic Surgeons (BAAPS), confirmed that 'Ozempic body' is now a recognized term in aesthetic medicine. Approximately 40% of patients seeking consultations are looking to address the impact of these weight-loss drugs.

The extent to which individuals experience 'post-jab sag' depends on factors such as age and skin elasticity. Younger individuals or those with thicker, darker skin may find their skin retains more resilience. However, older patients or those with thinner, fairer skin can experience a permanent loss of volume, leading to folds of loose tissue that exercise cannot correct.

For women, the impact on breasts can be particularly noticeable due to their fatty tissue composition. This can result in deflation of the upper breast pole, creating a flattened appearance or a 'ski slope' effect, with remaining tissue pooling at the bottom. Nugent added that the skin in this area can become stretched and thin, making reshaping and lifting more challenging and requiring a highly skilled surgeon.

While reconstructive procedures are on the rise, the trend in breast augmentation is moving away from exaggerated sizes. Patients are increasingly opting for smaller, more natural-looking implants, often described as 'ballerina boobs.' Surgeons report a preference for implants in the 200cc range, a decrease from historical averages that often exceeded 300cc. This shift aligns with the goal of restoring natural contours rather than achieving a significantly larger bust.

Many patients also seek to keep their procedures discreet, mirroring the secrecy that sometimes surrounds the use of weight-loss drugs. Some individuals have managed to keep cosmetic interventions hidden from partners and family.

New surgical techniques are also enhancing the results and recovery for breast procedures. Modern methods allow for same-day recovery for many augmentations, a contrast to the longer hospital stays previously required. Techniques such as injectable breast augmentations and fat transfer are being used to achieve more natural outcomes and minimize visible scarring.

However, undergoing cosmetic surgery after using GLP-1 medications presents specific considerations. Nugent highlighted that these drugs affect gastric emptying, altering how general anesthesia is administered. Standard pre-operative fasting instructions may not be sufficient, and patients might need to pause their medication. Additionally, weight stabilization is crucial. Surgeons ideally recommend that a patient's weight remain stable for at least six months before surgery to ensure the longevity and success of the results. Significant weight fluctuations after surgery can affect the appearance and integrity of the implants or tissue.

The increasing prevalence of rapid weight loss through GLP-1 medications suggests that the demand for surgical solutions to body contouring is not a fleeting trend but a new baseline in the field of cosmetic surgery.